Emergent BioSolutions offers specialized
products to healthcare providers and governments
to address medical needs and emerging
health threats.

Investor Toolkit

Recent NewsRSS 
DateTitleMore »
03/25/15Emergent BioSolutions Receives FDA Approval of Anthrasil, Its Anthrax Immune Globulin, for Use in the Treatment of Inhalational AnthraxPrinter Friendly Version
03/24/15Emergent BioSolutions Awarded $31 Million Contract for Advanced Development of NuThrax, a Next Generation Anthrax VaccinePrinter Friendly Version
03/16/15Emergent BioSolutions Signs Agreements With Oxford University, GlaxoSmithKline, and NIAID for the Production of an MVA Ebola Zaire Vaccine CandidatePrinter Friendly Version
03/09/15Emergent BioSolutions and MorphoSys Initiate Phase 1 Clinical Study to Evaluate the Novel Oncology Immunotherapeutic MOR209/ES414 for Prostate CancerPrinter Friendly Version
Annual Reports

A copy of the company’s Form 10-K, including the company’s completed audited financial statements, for the year ended December 31, 2013, filed with the Securities and Exchange Commission, is available without charge, upon written request to Investor Relations, Emergent BioSolutions Inc., Suite 400, Rockville, MD 20850.

Download DocumentationEmergent BioSolutions Inc. 2013 Annual Report
Download DocumentationEmergent BioSolutions Inc. 2013 Annual Report (Interactive)
Webcasts & Presentations
Date
Title
03/05/15
Download Documentation Q4 2014 Emergent BioSolutions Inc. Earnings Conference Call
01/20/15
Download Documentation Emergent BioSolutions Inc. at Noble Financial Equity Conference
01/12/15
Download Documentation Emergent BioSolutions Inc. at JPMorgan Healthcare Conference
12/10/14
Download Documentation Emergent BioSolutions Inc. at 25TH Annual Oppenheimer Healthcare Conference
Primary IR Contact
Robert G. Burrows
Vice President,
Investor Relations

Emergent BioSolutions Inc.
Phone: (240) 631 3280
Cell: (240) 413-1917
E-mail: burrowsr@ebsi.com
Transfer Agent
American Stock Transfer
& Trust Company

59 Maiden Lane
New York, NY 10038
Phone: (212) 936-5100
Website: http://www.amstock.com
Receive Email AlertsE-mail Alert Icon
Sign up to receive Email alerts whenever Emergent BioSolutions Inc. posts new information to the site. Just enter your Email address and click Submit.
 
Safe Harbor Statement
The documents contained in (or directly accessible from) this website include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including our financial guidance, and any other statements containing the words “believes”, “expects”, “anticipates”, “intends”, “plans”, “forecasts”, “estimates” and similar expressions in conjunction with, among other things, discussions of financial performance or financial condition, growth strategy, product sales, manufacturing capabilities, including our current investigation involving our suppliers and contract manufacturers regarding a discovery of foreign particles in two lots of BioThrax, product development, regulatory approvals or expenditures are forward-looking statements. These forward-looking statements are based on our current intentions, beliefs and expectations regarding future events. We cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement. There are a number of important factors that could cause the company’s actual results to differ materially from those indicated by such forward-looking statements, including the potential outcome of our current investigation of foreign particles discovered in two lots of BioThrax; appropriations for BioThrax procurement; our ability to successfully integrate Cangene Corporation and realize the potential benefits of this acquisition; our ability to obtain new BioThrax sales contracts or modifications to existing contracts; our plans to pursue label expansions and improvements for BioThrax; availability of funding for our US government grants and contracts; our ability to identify and acquire or in-license products or late-stage product candidates that satisfy our selection criteria; whether anticipated synergies and benefits from an acquisition or in-license are realized within expected time periods or at all; our ability to enter into selective collaboration arrangements; the timing of and our ability to achieve milestones in out-license and collaboration contracts; our ability to expand our manufacturing facilities and capabilities; our ability and the ability of our contractors and suppliers to maintain compliance with cGMP and other regulatory obligations; the results of regulatory inspections; our ability to meet operating and financial restrictions placed on us and our subsidiaries that are contained in our senior credit facility; the rate and degree of market acceptance and clinical utility of our products; the success of our ongoing and planned development programs; the timing of and our ability to obtain and maintain regulatory approvals for our product candidates; and our commercialization, marketing and manufacturing capabilities and strategy. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. Investors should consider this cautionary statement, as well as the risk factors identified in our periodic reports filed with the SEC, when evaluating our forward-looking statements. The company disclaims any intention or obligation to update any forward-looking statements contained in or directly accessible from documents on this website.
Data provided by Nasdaq. Minimum 15 minutes delayed.

Stock Quote

$28.76
Change (%) - 0.42 (1.44%)
Volume177,051
As of 03/31/15 4:02 p.m. ET
Minimum 15 minute delay
Refresh quote

EBD Listed NYSE